Evidence map›Paper›PMID 41368587›Full record

ArticleDrug design, development and therapy2025

Canagliflozin as a Potential Preclinical Therapy for Tuberous Sclerosis Complex: Inhibition of

Juan Ye, Boyuan Liu, Jing Wu, Hongliang Gao, Qingyun Wei, Kelei Su, Kai Zheng, Xuening Dai, Tao Xu, Yuqi Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Juan Ye *Medical School, Nanjing University Nanjing, Jiangsu, 210023, People's Republic of China.
Boyuan Liu *Sir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.ORCID 0000-0002-2463-3457
Jing Wu *Translational Medicine Research Center, Children's Hospital of Nanjing Medical University, Nanjing, 210000, People's Republic of China.
Hongliang GaoDepartment of Pathophysiology, Wannan Medical college, Wuhu, 241002,People's Republic of China.
Qingyun WeiAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210028, People's Republic of China.
Kelei SuAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210028, People's Republic of China.
Kai ZhengJiangsu Province Engineering Research Center of Stomatological Translational Medicine, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Xuening DaiSir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.
Tao XuSir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.
Yuqi WangSir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.
Shuangchi LiuDepartment of General Surgery, the Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, 213003, People's Republic of China.
Xing PengSir Run Run Hospital, Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China.ORCID 0009-0006-5173-8234
Liming GouTranslational Medicine Research Center, Children's Hospital of Nanjing Medical University, Nanjing, 210000, People's Republic of China.
Yinjuan Zhao *Collaborative Innovation Center of Sustainable Forestry in Southern China, College of Forestry, Nanjing Forestry University, Nanjing, 210037, People's Republic of China.
Bin XueMedical School, Nanjing University Nanjing, Jiangsu, 210023, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Canagliflozin (Ca), a sodium-glucose cotransporter 2 (SGLT2) inhibitor traditionally used for type 2 diabetes, has shown potential in the treatment of lymphangiomatosis (the pulmonary lesion phenotype of TSC). However, its effects on Methods: The effects of Ca on Results: Ca significantly inhibited Conclusion: Ca inhibits

Indexed as

CanagliflozinCell Cycle CheckpointsMitochondriaSodium-Glucose Transporter 2 InhibitorsTuberous SclerosisTuberous Sclerosis Complex 2 ProteinAnimalsCell ProliferationDose-Response Relationship, DrugHumansMaleMiceStructure-Activity RelationshipCanagliflozinSodium-Glucose Transporter 2 InhibitorsTSC2 protein, humanTsc2 protein, mouseTuberous Sclerosis Complex 2 Proteincanagliflozinmitochondrial impairmentrare diseasesTsc2 gene

Identifiers

PMID41368587
PMCPMC12684256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.